As of Nov. 15, 2023, three stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in pre-market trading.